174 related articles for article (PubMed ID: 21745378)
1. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.
Díaz-Lagares C; Pérez-Alvarez R; García-Hernández FJ; Ayala-Gutiérrez MM; Callejas JL; Martínez-Berriotxoa A; Rascón J; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Gómez-de-la-Torre R; Sáez L; Canora-Lebrato J; Camps MT; Ortego-Centeno N; Castillo-Palma MJ; Ramos-Casals M;
Arthritis Res Ther; 2011 Jul; 13(4):R112. PubMed ID: 21745378
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.
Ramos-Casals M; Brito-Zerón P; Muñoz S; Soto MJ;
Medicine (Baltimore); 2008 Nov; 87(6):345-364. PubMed ID: 19011506
[TBL] [Abstract][Full Text] [Related]
3. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
4. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
[TBL] [Abstract][Full Text] [Related]
5. [Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].
Proft F; Schulze-Koops H; Grunke M; Schrezenmeier E; Halleck F; Henes J; Unger L; Schmidt E; Fiehn C; Jacobi A; Iking-Konert C; Kneitz C; Schmidt RE; Bannert B; Voll RE; Fischer-Betz R; Kötter I; Tony HP; Holle J; Aringer M; Erler A; Behrens F; Burmester GR; Dörner T
Z Rheumatol; 2018 Feb; 77(1):28-39. PubMed ID: 28589389
[TBL] [Abstract][Full Text] [Related]
6. The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis.
Odler B; Windpessl M; Krall M; Steiner M; Riedl R; Hebesberger C; Ursli M; Zitt E; Lhotta K; Antlanger M; Cejka D; Gauckler P; Wiesholzer M; Saemann M; Rosenkranz AR; Eller K; Kronbichler A
Front Immunol; 2021; 12():760708. PubMed ID: 34777374
[TBL] [Abstract][Full Text] [Related]
7. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
8. Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
Toh S; Li L; Harrold LR; Bayliss EA; Curtis JR; Liu L; Chen L; Grijalva CG; Herrinton LJ
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):524-34. PubMed ID: 22411435
[TBL] [Abstract][Full Text] [Related]
9. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
10. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
Hässler S; Bachelet D; Duhaze J; Szely N; Gleizes A; Hacein-Bey Abina S; Aktas O; Auer M; Avouac J; Birchler M; Bouhnik Y; Brocq O; Buck-Martin D; Cadiot G; Carbonnel F; Chowers Y; Comabella M; Derfuss T; De Vries N; Donnellan N; Doukani A; Guger M; Hartung HP; Kubala Havrdova E; Hemmer B; Huizinga T; Ingenhoven K; Hyldgaard-Jensen PE; Jury EC; Khalil M; Kieseier B; Laurén A; Lindberg R; Loercher A; Maggi E; Manson J; Mauri C; Mohand Oumoussa B; Montalban X; Nachury M; Nytrova P; Richez C; Ryner M; Sellebjerg F; Sievers C; Sikkema D; Soubrier M; Tourdot S; Trang C; Vultaggio A; Warnke C; Spindeldreher S; Dönnes P; Hickling TP; Hincelin Mery A; Allez M; Deisenhammer F; Fogdell-Hahn A; Mariette X; Pallardy M; Broët P;
PLoS Med; 2020 Oct; 17(10):e1003348. PubMed ID: 33125391
[TBL] [Abstract][Full Text] [Related]
11. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
Mariette X; Gottenberg JE; Ravaud P; Combe B
Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
[TBL] [Abstract][Full Text] [Related]
12. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies.
Brito-Zerón P; Bosch X; Pérez-de-Lis M; Pérez-Álvarez R; Fraile G; Gheitasi H; Retamozo S; Bové A; Monclús E; Escoda O; Moreno A; López-Guillermo A; Khamashta MA; Ramos-Casals M;
Semin Arthritis Rheum; 2016 Feb; 45(4):391-9. PubMed ID: 26277577
[TBL] [Abstract][Full Text] [Related]
13. Dose down-titration of biological DMARDs in patients with rheumatoid arthritis over time and in daily clinical practice.
Rodriguez-Rodriguez L; Leon L; Lamas JR; Gomez A; Vadillo C; Blanco M; Jover JA; Abasolo L
Clin Exp Rheumatol; 2016; 34(5):872-879. PubMed ID: 27214094
[TBL] [Abstract][Full Text] [Related]
14. Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy.
Migita K; Arai T; Ishizuka N; Jiuchi Y; Sasaki Y; Izumi Y; Kiyokawa T; Suematsu E; Miyamura T; Tsutani H; Kawabe Y; Matsumura R; Mori S; Ohshima S; Yoshizawa S; Kawakami K; Suenaga Y; Nishimura H; Sugimoto T; Iwase H; Sawada H; Yamashita H; Kuratsu S; Ogushi F; Kawabata M; Matsui T; Furukawa H; Bito S; Tohma S
PLoS One; 2013; 8(11):e78699. PubMed ID: 24260127
[TBL] [Abstract][Full Text] [Related]
15. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults.
McAtee CL; Lubega J; Underbrink K; Curry K; Msaouel P; Barrow M; Muscal E; Lotze T; Srivaths P; Forbes LR; Allen C; Bernhardt MB
JAMA Netw Open; 2021 Feb; 4(2):e2036321. PubMed ID: 33533931
[TBL] [Abstract][Full Text] [Related]
16. Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases).
Gottenberg JE; Chaudier A; Allenbach Y; Mekinian A; Amoura Z; Cacoub P; Cornec D; Hachulla E; Quartier P; Melki I; Richez C; Seror R; Terrier B; Devauchelle-Pensec V; Henry J; Gatfosse M; Bouillet L; Gaigneux E; Andre V; Baulier G; Saunier A; Desmurs M; Poulet A; Ete M; Bienvenu B; Truchetet ME; Michaud M; Larroche C; Dellal A; Leurs A; Ottaviani S; Nielly H; Vial G; Jaussaud R; Rouvière B; Jeandel PY; Guffroy A; Korganow AS; Jouvray M; Meyer A; Chatelus E; Sordet C; Felten R; Sibilia J; Litim-Ahmed-Yahia S; Kleinmann JF; Mariette X
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36319066
[TBL] [Abstract][Full Text] [Related]
17. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
[TBL] [Abstract][Full Text] [Related]
18. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
19. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
20. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
